Poxel Announces Notice of its Annual General Meeting to be Held on June 23, 2021
19 Maggio 2021 - 11:00AM
Business Wire
POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical
company focused on the development of innovative treatments for
metabolic disorders, including type 2 diabetes and non-alcoholic
steatohepatitis (NASH) today announced the publication of the
meeting notice for the Annual General Meeting, which will take
place in a closed virtual session on June 23rd, 2021 at 1.00pm
CEST.
In the context of the COVID-19 pandemic and in accordance with
the regulations introduced to limit or prohibit travel and
collective gatherings to prevent the spread of the COVID-19 virus
(article 4 of Order n° 2020-321 of March 25, 2020 as amended and
extended and decree n° 2020-1310 of October 29, 2020 as amended and
extended including by the decree n° 2021-541 of May 1, 2021),
Poxel’s Board of Directors has decided to hold the 2021 Annual
General Meeting behind closed doors, without the physical presence
of shareholders. Therefore, the Company strongly encourages its
shareholders to use the resources made available to them to
exercise their voting rights remotely before the General Meeting by
voting by post or giving proxy.
A live webcast of the meeting will be available without
possibility to interact. The shareholders will be able to attend
the meeting by logging into:
https://us02web.zoom.us/webinar/register/WN_n3dJm667StmhBsqiG380RA
The meeting notice, the convening brochure, the 2020 Universal
Registration Document and the documents and information mentioned
in Article R. 225-73-1 of the French Commercial Code will be
available to shareholders on the Company’s website at least 21 days
before the meeting at the following link:
https://www.poxelpharma.com/en_us/investors/shareholder-information/annual-general-meeting-documents
The detailed procedures for participating remotely beforehand
and send written questions are available in the meeting notice n°
2101853, which was published in the BALO (French legal gazette) n°
60 dated May 19, 2021.
The results and presentation for the 2021 Annual General Meeting
will be available on Poxel’s website www.poxelpharma.com in the
Investors/Shareholder Information/Annual General Meeting Documents
section after the meeting.
About Poxel SA
Poxel is a dynamic biopharmaceutical company that uses its
extensive expertise in developing innovative drugs for metabolic
diseases, with a focus on type 2 diabetes and non-alcoholic
steatohepatitis (NASH), and selected rare inherited disorders
including adrenoleukodystrophy. In its mid-to-late-stage pipeline,
the Company is currently advancing three drug candidates; several
earlier-stage opportunities are also underway. Imeglimin, Poxel’s
first-in-class lead product, targets mitochondrial dysfunction.
Poxel has a strategic partnership with Sumitomo Dainippon Pharma
for Imeglimin in Japan, China, South Korea, Taiwan and nine other
Southeast Asian countries. A Japanese new drug application (J-NDA)
is under review by the Pharmaceuticals and Medical Devices Agency
(PMDA) to request approval for the manufacturing and marketing of
Imeglimin for the treatment of type 2 diabetes. After successfully
completing a Phase 2a proof-of-concept trial for the treatment of
NASH, which met its primary endpoint and study objectives, for
PXL770, a first-in-class direct adenosine monophosphate-activated
protein kinase (AMPK) activator, Poxel plans to initiate a Phase 2b
program in the second half of 2021. PXL770 could also have the
potential to treat additional metabolic diseases. PXL065
(deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a
streamlined Phase 2 trial for the treatment of NASH. Poxel also has
additional earlier-stage programs from its AMPK activator and
deuterated TZD platforms targeting chronic and rare metabolic
diseases. The Company intends to generate further growth through
strategic partnerships and pipeline development. Listed on Euronext
Paris, Poxel is headquartered in Lyon, France, and has subsidiaries
in Boston, MA, and Tokyo, Japan. For more information, please
visit: www.poxelpharma.com
In the context of the COVID-19 outbreak, which was declared a
pandemic by the World Health Organization (WHO) on March 12, 2020,
the Company is regularly reviewing the impact of the outbreak on
its business.
As of the date of this press release, and based on publicly
available information, the Company has not identified the
occurrence of any material negative effect on its business due to
the COVID-19 pandemic that remains unresolved. However, the Company
anticipates that the COVID-19 pandemic could have further material
negative impact on its business operations. The worldwide impact of
COVID-19 may notably affect the Company’s internal organization and
efficiency, particularly in countries where it operates and where
confinement measures are implemented by the authorities. In
addition, COVID-19 may impact market conditions and the Company’s
ability to seek additional funding or enter into partnerships.
Particularly, delays in the supply of drug substance or drug
products, in the initiation or the timing of results of preclinical
and/or clinical trials, as well as delays linked to the
responsiveness of regulatory authorities could occur, which could
potentially have an impact on the Company’s development programs
and partnered programs. The Company will continue to actively
monitor the situation.
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210519005379/en/
Poxel SA Catherine David Investor Relations &
Communication Manager catherine.david@poxelpharma.com +33 7 64 57
61 78
Investor relations / Media - EU/US Trophic Communications
Stephanie May or Valeria Fisher poxel@trophic.eu +49 171 185 56 82
or +49 175 804 1816
Investor relations / Media - France NewCap Emmanuel Huynh
or Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Apr 2023 a Apr 2024